The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 62 , ISSUE 1 ( January-March, 2020 ) > List of Articles


Are We Moving Towards Development of Universal Drug Regimen for Treatment of Tuberculosis?

Citation Information : Are We Moving Towards Development of Universal Drug Regimen for Treatment of Tuberculosis?. Indian J Chest Dis Allied Sci 2020; 62 (1):5-7.

DOI: 10.5005/ijcdas-62-1-5

License: CC BY-NC 4.0

Published Online: 07-11-2022

Copyright Statement:  Copyright © 2020; The Author(s).


PDF Share
  1. World Health Organization. Global Tuberculosis Report 2019. Geneva: WHO; 2019 (WHO/CDS/TB/2019.15). Available at URL: Accessed on: December 15, 2019.
  2. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new end TB strategy. Lancet 2015;385:1799–1801.
  3. Revised National Tuberculosis Control Programme. New Delhi, India: RNTCP; 2017. Central TB Division, Ministry of Health and Family Welfare, Government of India. National Strategic Plan for Tuberculosis Elimination 2017-2025. (Draft) Available at URL: 20.02.2017%201.pdf. Accessed on: December 16, 2019.
  4. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (October 2016 revision). (WHO/HTM/TB/2016.04). WHO, Geneva, 2016. Available at URL: am/10665/250125/1/9789241549639-eng.pdf. Accessed on: December 15, 2019.
  5. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO, Geneva, 2019 (WHO/CDS/TB/2019.7); Available at URL: guidelines-drug-resistant-TB-treatment/en/. Accessed on: December 22, 2019.
  6. Khan FA, Hamid Salim MA, du Cros P, Casas EC, Khamraev A, Sikhondze W, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J 2017;50:1700061.
  7. Moodley R, Godec TR. Short-course treatment for multidrugresistant tuberculosis: the STREAM trials. Eur Respir Rev 2016; 25:29–35.
  8. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med 2019;380:1201–13.
  9. Udwadia, ZF, Tornheim, JA, Ganatra S, DeLuca A, Rodrigues CS, Gupta A, et al. Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic. BMC Infect Dis 2019;19:94.
  10. Research Excellence to Stop TB Resistance. Drug-resistant tuberculosis: clinical trials progress report. RESIST TB,
  11. Available at URL: Accessed on: June 14, 2019.
  12. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol 2009;2:215–8.
  13. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020;382:893–902.
  14. D iacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380(9846):986–93.
  15. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), andpyrazinamide during the first 8 weeks of anti-tuberculosis treatment: a phase 2b, openlabel, partly randomised trial inpatients with drug-susceptible or drug-resistant pulmonarytuberculosis. Lancet 2015;385:1738–48.
  16. T weed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med 2019;7:1048–58.
  17. Wallis R S, Cohen T, Menzies N A, Churchyard G. Pantuberculosis regimens: an argument for. Lancet Respir Med 2018;6:239–40.
  18. D heda K, Gumbo T, Lange C, Horsburgh C R, Furin J. Pantuberculosis regimens: an argument against. Lancet Respir Med 2018;6:240–42.
  19. S hrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, et al. Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis. Open Forum Infect Dis 2014;1:ofu073.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.